Lung volume reduction for severe COPD - surgery or valves, decided properly.
A thoracic MDT decides whether VATS LVRS, endobronchial valves or optimised medical therapy is the right next step - under NICE NG115 and BTS criteria, at a centre that does enough of these to be good at them.
Indicative pricing
What LVRS and endobronchial valves cost in the UK.
Both LVRS and EBV are NHS-funded when NICE NG115 and BTS criteria are met.
In short
Private bilateral VATS LVRS: £18,000–£30,000. Endobronchial valves: £8,000–£14,000.
| Procedure | Indicative range | Typical duration | Inpatient stay |
|---|---|---|---|
| Bilateral VATS LVRS (private) | £18,000–£30,000 | 2–4 hrs theatre | 7–14 days inpatient |
| Unilateral VATS LVRS (private) | £15,000–£22,000 | 2–3 hrs theatre | 5–10 days inpatient |
| Endobronchial valves (Zephyr / Spiration) | £8,000–£14,000 | 45–90 min bronch | 3–5 days inpatient |
| Chartis fissure assessment (bronchoscopy) | £2,000–£3,500 | 30–45 min | Day-case |
| Pre-op work-up (HRCT, PFT, 6MWT, echo) | £1,200–£2,200 | Half-day | Same week |
| Thoracic MDT opinion only | £350–£650 | 45 min | 1–2 weeks |
Prices vary by centre, by whether a Chartis assessment is needed first, and by the length of stay driven by any air leak.
The problem
The right patient, the right procedure, the right centre.
LVRS and EBV are transformative for the right phenotype and harmful for the wrong one. Selection is the whole game - pulmonary rehab first, MDT decision, and a centre that does this every week.
-
Not sure it is you?
A short phone triage against NICE NG115 and BTS criteria - before you spend on scans or fly in for an appointment.
-
Valves or surgery?
A Chartis assessment and HRCT read together decide it.
-
Want a centre that does it enough?
A small panel of UK thoracic units with weekly LVRS MDTs and an active EBV programme - not general thoracic dabbling.
When it helps
Who benefits from LVRS or endobronchial valves.
The criteria that decide it - from NICE NG115 and BTS - plus the one red flag that stops the pathway before it starts.
-
Severe COPD despite maximal therapy
FEV1 20–45% predicted on long-acting bronchodilators and inhaled steroids - still breathless walking on the flat.
-
Upper-lobe heterogeneous emphysema
The classic HRCT pattern that benefits most from LVRS - destroyed upper lobes squashing better lower lobes.
-
Hyperinflation on lung function
Total lung capacity above 120% predicted and residual volume above 150–180% - the diaphragm is flattened and mechanically inefficient.
-
DLCO above 20% predicted
Gas transfer needs to be preserved enough to survive the operation. Below 20%, risk climbs sharply.
-
6-minute walk above 140 m
You need enough baseline exercise capacity to complete rehab and recover from surgery.
-
Motivated and rehab-completed
You have stopped smoking, completed pulmonary rehab, and are prepared for a hard admission with a real payoff.
-
Considering valves (EBV) instead
Heterogeneous emphysema with an intact interlobar fissure on CT may be better served bronchoscopically - no ports, no drains, day-case return home.
-
Red flag: still smoking
Neither LVRS nor valves are offered while you smoke. Smoking cessation is the entry ticket, not a nice-to-have.
Procedure options
LVRS is not the only option.
What each option on the table actually involves - and which anatomy or phenotype fits which procedure.
-
Bilateral VATS LVRS
The commonest approach. Wedge resections of 20–30% of the most hyperinflated tissue on both sides, staple lines reinforced with bovine pericardium.
-
Unilateral VATS LVRS
For asymmetric disease - one side worse than the other, or a previous pleurodesis on one side.
-
Median sternotomy LVRS
The historical open approach. Rarely used today, kept for cases where VATS is not feasible.
-
Endobronchial valves (Zephyr)
One-way umbrella valves placed bronchoscopically to collapse a hyperinflated lobe - no incisions, no drains at the outset.
-
Endobronchial valves (Spiration)
Umbrella-shaped valves, similar principle, alternative anatomy fit. Choice depends on airway shape and centre expertise.
-
Chartis fissure assessment
Bronchoscopic measurement of collateral ventilation. Positive fissure integrity is essential before EBV - no fissure, no valves.
-
Bronchoscopic coils / vapour
Investigational or limited-access alternatives - coils, thermal vapour ablation, biological polymers. Not standard NHS.
-
Lung transplant
The alternative for younger patients with end-stage disease and few comorbidities. A separate, longer road.
Safety and recovery
What to expect afterwards - honestly.
LVRS and EBV are transformative but not benign. Prolonged air leak is common, mortality is real, and the recovery is measured in months, not days.
-
Prolonged air leak is common
Twenty to forty per cent of LVRS patients have a leak that persists beyond seven days. It is the commonest reason a stay stretches to two weeks.
-
Pneumonia and atelectasis
Aggressive physiotherapy, early mobilisation and adequate pain control are the antidote - they are why the unit choice matters.
-
Cardiac arrhythmia
Atrial fibrillation is common after thoracic surgery - around one in five. Usually treated on the ward and settles.
-
Pneumothorax after drain out
A small proportion re-collect a pneumothorax when the drain comes out. Watched carefully, drained again if needed.
-
Empyema and VTE
Chest infection and clot risk are managed with antibiotics, prophylactic heparin and early mobilisation.
-
30-day mortality: 2–5%
Real. Lower in the classic NETT-eligible subgroup (upper-lobe, low exercise capacity), higher outside it - which is why selection is everything.
-
EBV-specific risks
Pneumothorax in 20–30% (usually early), valve migration or expectoration, cough, pneumonia distal to the valve, and need for repeat bronchoscopy.
-
The NETT "high-risk" subgroup
FEV1 below 20% with homogeneous emphysema and DLCO below 20% had unacceptable mortality in the NETT trial. NICE excludes this group from LVRS.
-
Red flags after discharge
New fever, spreading redness at a port site, sudden severe breathlessness, chest pain or blood in the sputum - call the team or A&E the same day.
Reading your operation note
Your operation note in four parts. Read the last one first.
Whether you had bilateral VATS LVRS or endobronchial valves, the note the thoracic team sends you keeps to the same shape.
A quiet reminder
Thoracic language is precise and can read coldly - we translate it for you.
If you would like us to talk you through the note before your review, just ask.
- 01 Header
Indication and pathway chosen
Why the procedure was done - severe COPD phenotype, HRCT findings, PFT numbers - and whether LVRS or EBV was the agreed step.
- 02 Technique
Approach, resection and staple lines
VATS or open, unilateral or bilateral, which lobes were reduced, how much tissue was removed and whether the staple lines were buttressed.
- 03 Findings
Air leak, drains and immediate course
Duration of air leak, number and position of chest drains, ITU stay, any arrhythmia or pneumonia, and inpatient FEV1 trend.
- 04 Impression
Rehab plan and follow-up timing
Read this first: continued pulmonary rehab, when to expect FEV1 gain, review at 6 weeks, 3 months and 12 months, and what would prompt earlier contact.
Recognised by major UK insurers
Cover for LVRS and EBV varies by insurer and by evidence of eligibility. Most policies fund the pathway when NICE NG115 and BTS criteria are met.
Frequently asked
Everything we get asked about LVRS and endobronchial valves.
Quick answers on eligibility, valves versus surgery, risk, recovery and cost.
-
Who is lung volume reduction surgery actually for?
People with severe COPD (FEV1 roughly 20–45% predicted), heterogeneous upper-lobe emphysema on HRCT, marked hyperinflation (TLC above 120%, RV above 150–180%), DLCO above 20% predicted and a 6-minute walk above 140 m - who have stopped smoking, completed pulmonary rehab and remain limited by breathlessness. Selection is everything: the wrong phenotype does worse with surgery than without.
-
What is the difference between LVRS and endobronchial valves?
LVRS is surgery - VATS ports, wedge resections, chest drains and a week or two in hospital. Endobronchial valves (EBV - Zephyr or Spiration) are placed at bronchoscopy with no incisions, collapsing a hyperinflated lobe from the inside. EBV suits patients with intact interlobar fissures (confirmed at Chartis assessment) and gives comparable outcomes to LVRS in the right anatomy, with a shorter admission.
-
How much does private LVRS or EBV cost in the UK?
Roughly £18,000–£30,000 for a bilateral VATS LVRS admission privately, £15,000–£22,000 unilateral, and £8,000–£14,000 for endobronchial valves. Chartis assessment adds £2,000–£3,500. Both procedures are NHS-funded per NICE NG115 and BTS criteria when the phenotype fits.
-
Do I have to do pulmonary rehab first?
Yes. Six to eight weeks of structured pulmonary rehab is the entry ticket to both LVRS and EBV - it improves outcomes, reduces complications, and makes the recovery survivable. Skipping it is not an option in a serious centre.
-
What benefit can I expect?
Selected patients gain roughly 20–30% in FEV1 at twelve months, a meaningful drop in breathlessness on the mMRC scale, further on the 6-minute walk, and better quality of life. The NETT trial also showed a survival benefit in the upper-lobe, low-exercise-capacity subgroup versus best medical therapy alone.
-
What are the main risks?
Prolonged air leak (20–40%, the main reason admissions stretch), pneumonia, atrial fibrillation (around 20%), pneumothorax after drain removal, empyema, VTE and 30-day mortality of 2–5% in appropriately selected patients. The NETT "high-risk" subgroup - FEV1 below 20% with homogeneous emphysema and DLCO below 20% - is excluded because mortality was unacceptable.
-
How long will I be in hospital?
Around 24–48 hours in ITU or HDU, then on the thoracic ward until the chest drains come out. Total stay is typically seven to fourteen days for LVRS, three to five for EBV. Gentle activity from four to six weeks, back to normal by two to three months.
-
Can I have LVRS if I still smoke?
No. Ongoing smoking is a hard contraindication for both LVRS and EBV. You will be asked for biochemical evidence of cessation (cotinine or CO) before the MDT will list you.
-
What if I am too high-risk for LVRS?
The alternatives are endobronchial valves (bronchoscopic, lower-risk, right anatomy needed), optimised medical therapy with pulmonary rehab, ambulatory oxygen if hypoxic on 6MWT, and - for the right younger patient - assessment for lung transplant.
-
When should I seek urgent help after discharge?
New fever, spreading redness at a port site, sudden severe breathlessness (especially after a valve procedure - think pneumothorax), chest pain, coughing up blood or expectorating a valve are all reasons to contact the team or attend A&E the same day.
Related treatments